| Literature DB >> 34199846 |
Josselin Brisset1,2, Yvan Jamilloux3, Stephanie Dumonteil1, Guillaume Lades4, Martin Killian5, Mathieu Gerfaud-Valentin3, Anne Lemaire6, Tomasz Chroboczek7, Eric Liozon1, Guillaume Gondran1, Pascal Sève3, Jacques Monteil4, Anne-Laure Fauchais1, Kim Heang Ly1.
Abstract
While the diagnosis of adult-onset Still's disease (AOSD) involves the exclusion of differential diagnoses, the characteristics and value of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography coupled with CT (PET/CT) in the management of AOSD remain poorly known. Our retrospective study included patients from four centers, fulfilling Yamaguchi or Fautrel criteria, who underwent a PET/CT during an active AOSD. Thirty-five patients were included. At the time of PET/CT, the Yamaguchi criteria were met in 23 of 29 evaluable cases. PET/CT showed bone marrow (74.3%), lymph node (74.3%), and splenic (48.6%) FDG uptake. Despite arthralgia or arthritis in most patients, joints were rarely the sites of 18F-FDG accumulation. The spatial distribution of 18F-FDG uptake was nonspecific, and its intensity could be similar to malignant disease. Lymph node or bone marrow biopsy was performed after PET/CT in 20 patients (57.1%). The intensity of bone marrow; splenic and lymph node hypermetabolism appeared to be correlated with disease activity. Abnormal PET/CT in the cervical lymph nodes and age ≥ 60 years seemed to be predictive factors for monocyclic evolution. The clinical value of PET/CT is not in direct diagnosis; but as an aid in excluding differential diagnoses by searching for their scintigraphic features and guiding biopsy.Entities:
Keywords: 18F-FDG PET/CT; adult-onset Still’s disease
Year: 2021 PMID: 34199846 DOI: 10.3390/jcm10112489
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241